Healthy Individuals
Conditions
Brief summary
Gut microbiota play a key role in polyphenol metabolism, participating in the breakdown of dietary components and producing various small molecule metabolites that affect human health. However, little is currently known about how gut microbes metabolize dietary compounds and produce bioactive metabolites. This study aims to use metabolomics to precisely identify food-derived metabolites in the blood to investigate whether probiotics (BLa80, LRa05) can enhance the breakdown of dietary components and improve their absorption and utilization in the human body.
Interventions
DIETARY_SUPPLEMENTPlacebo
The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).
DIETARY_SUPPLEMENTBLa80
The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).
DIETARY_SUPPLEMENTLRa05
The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).
Sponsors
Wecare Probiotics Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female participants aged 18 to 60 years; 2. Healthy individuals; 3. Participants must provide written informed consent.
Exclusion criteria
1. History of gastrointestinal surgery, other gastrointestinal diseases, metabolic disorders, immunodeficiency, hyperthyroidism, or cardiac or liver disease; 2. Use of immunosuppressants; 3. Pregnant or breastfeeding women; 4. Participants who have taken antibiotics or probiotics within the previous 3 months; 5. Planned surgery during the study period; 6. Patients with neurological disorders or psychiatric illness.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum metabolomic profiles measured by HPLC-MS/MS | Baseline (week 0), week 4, and week 8 post intervention | Untargeted serum metabolomic profiling will be performed using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) to assess changes in circulating metabolite concentrations over time. |
Countries
China
Outcome results
None listed